PLX trade ideas
mid term +15,000%Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease.
$PLX - Inv SHS opportunity (EC tomorrow, BLA approval Apr27)Trigger above 5.5 (To the next resistance 5.8).
Very risky as well as catalysts opportunity movement.
Not recommended to buy or Sell PLX stocks!
Ready For A PopSteady accumulation over the last few weeks - looking ready to run with fundamentals catalysts of PDUFA and final Phase 3 data readout for PRX-102 in April
PLX Releases Phase 3 Trial Data tomorrow at 1:24 pm ESTPlease don't miss out on this one. If you are already a follower of me, you know that phase 3 trial data means very good things. Take a look at my idea on GMDA. like and follow for more picks like this!
$PLX - "Buy on rumor sell on news"?, Yet, BLA and BRIGHT aheadProtalix presented a good results yesterday on top line results with BRIDGE (Switch over from Refagal),
Link is below:
protalixbiotherapeutics.gcs-web.com
At this point, the main support is 5.29$ (Golden Pocket support)
Gap open below at 4.91
With expectation to the reversal .
Not recommended to buy or sell PLX stocks.
$PLX - One of my faves, Creating Positive MomentumPLX Could Claim Substantial Global Market Share In Fabry Disease.
April 27, BLA approval opportunity.
Technically, resistances in rage, 4.87 and 5.2.
Support level 4.4-4.35.
Not recommended to buy or sell PLX stocks (Very risky).
Just an Idea.
$PLX - The most important year for PROTALIX Final FDA decision for BLA approval will take place on April 27.
In terms of technical aspects:
Bullish flag opportunity on sight, trigger for long with breaking above 4.74.
Main support 4.35-4.4
Not recommended to buy or sell PLX stocks.
Very risky stock and stage,
Heavy sigh..PLX at its best.. 0 volume and 0 pressure upwards. Tons of downward pressure..!! Who would sell at these levels??? Short this?? Ok.. Looks bad till January?? Maybe.. we turn a corner.. Upwards.. Maybe..
Tomorrow may tell..As most of us know this stock doesn't deal well with resistance !! So..after poking through support I really have no idea what will happen tomorrow. I am invested in this and like many cant seem to understand why this stock has such weak abilities. Hopefully... it draws some buyers here soon and can rise above support. But it may just keep dipping lower till closer to Jan 26th. I believe thats the date. Anyone who has held this for yrs... myself included. Lets try and gather our strength and hold out for at least 8.49!! Sigh
$PLX - Positive scenario with breaking above 4.05$ (Inv SHS)Horizontal supports remains - 3.7, MA200 and 3.5
Not for any advise
Just an Idea.
$PLX - Who see that? Inv SHS? well, an OptionTarget to 4.77
Support 3.7 , below is 3.5
Not for any Advise
Just an Idea,
$PLX - Whoever followed me on that one (Staying for long)
3.35 was a good support + MA200
Not for any advise
Just an Idea,
$PLX - MA200 is the support? No volume hereHorizontal support set to 3.35.
Not for any advise
Just an Idea?
$PLX - Turtle progress (Today's announcement - read below)CARMIEL, Israel, August 24, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE
American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development,
production and commercialization of recombinant therapeutic proteins produced by its
proprietary ProCellEx® plant cell-based protein expression system, today announced completion
of the treatment period of its Phase III BRIGHT clinical trial of pegunigalsidase alfa, or
PRX-102, for the proposed treatment of Fabry disease. The Company is currently working with
its service providers to complete the final monitoring visits necessary for final analysis of the
data; however, many sites are still impacted by ongoing local and state restrictions and
precautions due to the COVID-19 pandemic. The Company anticipates announcing top-line
results in the fourth quarter of 2020 once this process is completed.
“Completion of the BRIGHT study marks another important key milestone in our pursuit of an
alternative dose and regimen of pegunigalsidase alfa for the proposed treatment of Fabry
disease,” said Dror Bashan, President and Chief Executive Officer of Protalix BioTherapeutics.
“We eagerly anticipate announcement of top-line data, and are working towards the completion
of the final monitoring visits as quickly as possible. Our challenge now is to continue the work to
finalize these last details with the ongoing headwinds from COVID-19. I am very proud of our
team’s execution in completing the study and am confident in their ability to have the final data
as expeditiously as possible.”
Mr. Bashan continued, “The BRIGHT study is the second Phase III study of PRX-102 in Fabry
patients that we have completed as part of our comprehensive PRX-102 development program.
We announced positive results earlier this year from our Phase III BRIDGE clinical trial, and we
anticipate results from an interim analysis of our Phase III BALANCE clinical trial in the first
half of 2021. In addition, earlier this month, we announced the filing of the PRX-102 BLA by the
U.S. Food and Drug Administration with a PDUFA target date of January 27, 2021.”
Very Risky stock
Not for any advise
$PLX -PDUFA date was set to Jan27 2021, Now it's out of the coneAiming to target 4.87
Not for any Advise
Just an Idea.
$PLX - Just updating the Chart, still inside the cone pattern3.6 is the main support now and still inside the cone pattern.
Till FDA respond, expect to a roller coaster effects.
Not for any advice
Just an Idea.
$PLX - As I already wrote so - soon PDUFA date or CRLBreaking the upper line.
Nice one.
Not for any advice
Just an Idea.
Holding from very below price.
$PLX - 11 days~ to PDUFA Date or CRL respond (From FDA)Continue follow-up (and holding)
Need more volume
3.44 approved as support.
Not for any advise
Just an Idea
